Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development
NCT ID: NCT06847932
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
14726 participants
INTERVENTIONAL
2025-07-01
2026-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection
NCT05127460
Predicting Disease Progression in Atrial Fibrillation: A Multiparametric Approach for Prognostic Marker Identification and Personalized Patient Management
NCT06647914
A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.
NCT04045639
KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation
NCT05407415
REVEAL AF: Incidence of AF in High Risk Patients
NCT01727297
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AF-predict AI-ECG alert system
All the patients' ECGs will receive AF-predict AI-ECG analysis. According to the AI-ECG analysis results, those with at least one high-risk ECG within one year will be called back and asked to undergo a continuous cardiac rhythm monitor for up to 7 days. Otherwise, the physicians can review the AI-ECG analysis results for all the patients in the intervention group.
AF-predict AI-ECG alert system guided management
AF-predict AI-ECG alert system
Standard of care
Patients will receive the standard care, and their ECGs will not be analyzed by AI-ECG before the end of the study.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AF-predict AI-ECG alert system guided management
AF-predict AI-ECG alert system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients need to have at least one electrocardiogram within one year
Exclusion Criteria
* History of atrial fibrillation/atrial flutter catheter ablation
* Patients with cardiac implantable electronic devices
* Any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm
* History of received rhythm control medications for atrial arrhythmia, including Class I and Class III antiarrhythmic drugs
* Any reasons indicate for anti-coagulant agents, including vitamin K antagonist and non-vitamin K antagonist oral anticoagulant
40 Days
85 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Defense Medical Center, Taiwan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chin Lin
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chin Lin, PhD
Role: PRINCIPAL_INVESTIGATOR
National Defense Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tri-Service General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A202205179
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.